• Publications
  • Influence
IDH1 and IDH2 mutations in gliomas.
BACKGROUND A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in aExpand
  • 2,522
  • 134
  • PDF
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
PURPOSE We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. Expand
  • 1,992
  • 100
  • PDF
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
PURPOSE The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody toExpand
  • 1,268
  • 39
  • PDF
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most commonExpand
  • 452
  • 34
  • PDF
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if theExpand
  • 1,005
  • 28
  • PDF
Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study.
Fifty-five patients with atypical teratoid/rhabdoid tumors of the central nervous system were studied to define the clinical and pathologic features of this newly described neoplasm. The lesionExpand
  • 378
  • 28
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme atExpand
  • 877
  • 27
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
BACKGROUND Among patients with malignant brain tumors, infants and very young children have the worst prognosis and the most severe treatment-related neurotoxic effects. Therefore, in 1986, theExpand
  • 708
  • 24
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
PURPOSE Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is aExpand
  • 607
  • 23
  • PDF
Temozolomide and treatment of malignant glioma.
Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) occur more frequently than other types of primary central nervous system tumors, having a combined incidence of 5-8/100,000Expand
  • 541
  • 21
  • PDF